EUVIMEDEUVIMED entdecken
Crossref

Targeted α-Therapy Using 225 Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment

Thomas Ertveldt, Ahmet Krasniqi, Hannelore Ceuppens, Janik Puttemans, Yana Dekempeneer, Kevin De Jonghe, Wout de Mey, Quentin Lecocq, Yannick De Vlaeminck, Robin Maximilian Awad, Cleo Goyvaerts, Kim De Veirman und 6 weitere

Journal of Nuclear Medicine · 2023-05 · 64 (5) · 751-758

DOI: 10.2967/jnumed.122.264752 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 13.04.2023. Verfasst von Thomas Ertveldt und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Melanoma, Experimental. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted radionuclide therapy (TRT) using targeting moieties labeled with α-particle-emitting radionuclides (α-TRT) is an intensely investigated treatment approach as the short range of α-particles allows effective treatment of local lesions and micrometastases. However, profound assessment of the immunomodulatory effect of α-TRT is lacking in literature.

Methods

Using flow cytometry of tumors, splenocyte restimulation, and multiplex analysis of blood serum, we studied immunologic responses ensuing from TRT with an antihuman CD20 single-domain antibody radiolabeled with 225Ac in a human CD20 and ovalbumin expressing B16-melanoma model.

Results

Tumor growth was delayed with α-TRT and increased blood levels of various cytokines such as interferon-γ, C-C motif chemokine ligand 5, granulocyte-macrophage colony-stimulating factor, and monocyte chemoattractant protein-1. Peripheral antitumoral T-cell responses were detected on α-TRT. At the tumor site, α-TRT modulated the cold tumor microenvironment (TME) to a more hospitable and hot habitat for antitumoral immune cells, characterized by a decrease in protumoral alternatively activated macrophages and an increase in antitumoral macrophages and dendritic cells. We also showed that α-TRT increased the percentage of programmed death-ligand 1 (PD-L1)-positive (PD-L1pos) immune cells in the TME. To circumvent this immunosuppressive countermeasure we applied immune checkpoint blockade of the programmed cell death protein 1-PD-L1 axis. Combination of α-TRT with PD-L1 blockade potentiated the therapeutic effect, however, the combination aggravated adverse events. A long-term toxicity study revealed severe kidney damage ensuing from α-TRT.

Conclusion

These data suggest that α-TRT alters the TME and induces systemic antitumoral immune responses, which explains why immune checkpoint blockade enhances the therapeutic effect of α-TRT. However, further optimization is warranted to avoid adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesMelanoma, ExperimentalAnimalsHumansB7-H1 AntigenTumor MicroenvironmentImmune Checkpoint InhibitorsImmunomodulationImmunityCell Line, Tumor

Stichwörter der Autor:innen

actinium-225immunologyoncologyradionuclide therapysingle-domain antibody

Substanzen

Single-Domain AntibodiesB7-H1 AntigenImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium.
  • Department of Medical Imaging, In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium.
  • Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium.
  • European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe Institut, Germany; and.
  • Department of Nuclear Medicine, UZ Brussel, Brussels, Belgium.
  • Department of Biomedical Sciences, Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium; Karine.Breckpot@vub.be.

Zitieren

APA

Ertveldt, T., Krasniqi, A., Ceuppens, H., Puttemans, J., Dekempeneer, Y., Jonghe, K., Mey, W., Lecocq, Q., Vlaeminck, Y., Awad, R. M., Goyvaerts, C., Veirman, K., Morgenstern, A., Bruchertseifer, F., Keyaerts, M., Devoogdt, N., D'Huyvetter, M., & Breckpot, K. (2023). Targeted α-Therapy Using 225 Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment. Journal of Nuclear Medicine, 64(5), 751-758. https://doi.org/10.2967/jnumed.122.264752

Vancouver

Ertveldt T, Krasniqi A, Ceuppens H, Puttemans J, Dekempeneer Y, Jonghe K, et al. Targeted α-Therapy Using 225 Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment. Journal of Nuclear Medicine. 2023;64(5):751-758. doi:10.2967/jnumed.122.264752

BibTeX
@article{Ertveldt2023,
  author = {Ertveldt, Thomas and Krasniqi, Ahmet and Ceuppens, Hannelore and Puttemans, Janik and Dekempeneer, Yana and Jonghe, Kevin De and Mey, Wout de and Lecocq, Quentin and Vlaeminck, Yannick De and Awad, Robin Maximilian and Goyvaerts, Cleo and Veirman, Kim De and Morgenstern, Alfred and Bruchertseifer, Frank and Keyaerts, Marleen and Devoogdt, Nick and D'Huyvetter, Matthias and Breckpot, Karine},
  title = {Targeted α-Therapy Using 225 Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {5},
  pages = {751--758},
  doi = {10.2967/jnumed.122.264752}
}
Kostenlos starten →